Metraipolis › archive › dc_5e7f7edbb545

Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations — Europe PMC PMID:42652989

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42652989
DOI
10.3390/life16081301
License (as archived)
solo-consultazione
Archived
2026-10-16T23:03:26.081Z
SHA-256 of the archived text
5d4f85be854a6d57b020cd5eadcb20e9c9f4e201525d6ecc9d1453a90babbc9a
Stable URL of this page
https://metraipolis.com/documento/dc_5e7f7edbb545

How to cite

Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations — Europe PMC PMID:42652989 — Europe PMC (en), https://europepmc.org/article/MED/42652989 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5e7f7edbb545 (Metraipolis archive dc_5e7f7edbb545, sha256 5d4f85be854a6d57b020cd5eadcb20e9c9f4e201525d6ecc9d1453a90babbc9a)
BibTeX
@misc{dc5e7f7edbb545,
  title = {Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations — Europe PMC PMID:42652989},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42652989},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5e7f7edbb545; sha256 5d4f85be854a6d57b020cd5eadcb20e9c9f4e201525d6ecc9d1453a90babbc9a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42652989. Agents can read the archived copy with the MCP tool read_document.